Table 3. Predictors of limitations in sports and daily activities (physical function score <45) from two multivariable regression models in survivors.
Limited in sports | Limited in daily activities | ||||||||||
%a | OR | 95% CI | pc | %b | OR | 95% CI | pc | ||||
Gender | 0.367 | 0.158 | |||||||||
Male | 8.5 | 1 | 13.2 | 1 | |||||||
Female | 10.5 | 1.23 | 0.78 | 1.95 | 16.7 | 1.31 | 0.90 | 1.90 | |||
Current age (years) | 0.061 | 0.496 | |||||||||
≤20 | 10.3 | 1.13 | 0.62 | 2.07 | 19.0 | 1.45 | 0.90 | 2.32 | |||
20–29.9 | 9.7 | 1 | 13.5 | 1 | |||||||
30–39.9 | 6.5 | 0.63 | 0.32 | 1.22 | 14.6 | 1.05 | 0.64 | 1.72 | |||
≥40 | 20.5 | 2.70 | 1.02 | 7.16 | 15.4 | 0.97 | 0.36 | 2.63 | |||
Parents education | 0.035 | 0.008 | |||||||||
Primary education | 4.6 | 0.40 | 0.13 | 1.18 | 20.5 | 1.89 | 1.03 | 3.49 | |||
Secondary education | 9.8 | 1 | 13.7 | 1 | |||||||
Tertiary education | 8.9 | 0.98 | 0.51 | 1.87 | 12.6 | 1.01 | 0.58 | 1.76 | |||
Unknown | 15.9 | 2.97 | 1.19 | 7.39 | 26.6 | 2.80 | 1.46 | 5.38 | |||
Age at diagnosis (years) | 0.964 | 0.387 | |||||||||
<5 | 8.1 | 1 | 14.6 | 1 | |||||||
5–9.9 | 9.7 | 1.04 | 0.55 | 1.97 | 14.3 | 0.72 | 0.43 | 1.19 | |||
≥10 | 10.7 | 1.10 | 0.56 | 2.14 | 15.6 | 0.92 | 0.54 | 1.56 | |||
Diagnosis (ICCC3 main groups) | <0.001 | <0.001 | |||||||||
I Leukemia | 4.0 | 1 | 9.2 | 1 | |||||||
II Lymphoma | 5.7 | 1.16 | 0.49 | 2.74 | 8.2 | 0.89 | 0.45 | 1.75 | |||
III CNS tumor | 23.2 | 9.40 | 4.26 | 20.74 | 30.5 | 5.76 | 3.08 | 10.80 | |||
IV Neuroblastoma | 11.1 | 3.77 | 1.23 | 11.55 | 15.6 | 2.42 | 0.95 | 6.17 | |||
V Retinoblastoma | 19.1 | 8.55 | 2.26 | 32.33 | 19.1 | 2.88 | 0.82 | 10.10 | |||
VI & VII Renal & hepatic tumord | 6.8 | 1.65 | 0.57 | 4.80 | 16.0 | 2.19 | 1.04 | 4.63 | |||
VIII Bone tumor | 34.2 | 13.59 | 5.55 | 33.28 | 45.2 | 10.87 | 5.04 | 23.45 | |||
IX Soft tissue sarcoma | 12.7 | 2.87 | 1.07 | 7.70 | 16.1 | 1.76 | 0.77 | 4.04 | |||
X Germ cell tumor | 6.9 | 2.11 | 0.44 | 10.12 | 10.0 | 1.15 | 0.31 | 4.19 | |||
XI & XII Other tumore | 18.2 | 5.72 | 1.03 | 31.76 | 16.7 | 1.86 | 0.34 | 10.02 | |||
Langerhans Cell Histiocytosis | 4.4 | 1.62 | 0.35 | 7.52 | 15.2 | 2.91 | 1.15 | 7.35 | |||
Treatment | <0.001 | <0.001 | |||||||||
Surgery only | 8.2 | 0.35 | 0.13 | 0.90 | 13.2 | 0.50 | 0.23 | 1.07 | |||
Chemotherapyf | 7.0 | 1 | 10.3 | 1 | |||||||
Radiotherapyg | 13.6 | 1.61 | 0.90 | 2.88 | 20.6 | 2.08 | 1.31 | 3.32 | |||
Bone marrow transplantation | 8.1 | 0.85 | 0.22 | 3.28 | 25.6 | 2.98 | 1.24 | 7.14 | |||
Relapse | 0.880 | 0.326 | |||||||||
No | 9.3 | 1 | 14.2 | 1 | |||||||
Yes | 11.3 | 1.06 | 0.52 | 2.13 | 20.6 | 1.32 | 0.76 | 2.29 |
Abbreviations: CI, Confidence Interval; CNS, Central Nervous System; ICCC-3, International Classification of Childhood Cancer Third Edition; OR, Odds Ratio.
Proportion reporting a limitation in sports in each stratum. Column percentages are given.
Proportion reporting a limitation in daily activities in each stratum. Column percentages are given.
Global p-values calculated with a likelihood ratio test.
Hepatic and renal tumors have been merged for this analysis.
Other malignant epithelial neoplasm, malignant melanoma and other or unspecified malignant neoplasm.
Chemotherapy may include surgery.
Radiotherapy may include surgery and/or chemotherapy.